Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $79,214 | $159,514 | $158,216 | $152,839 |
| - Cash | $10,449 | $4,415 | $1,562 | $11,582 |
| + Debt | $10,768 | $811 | $251 | $75 |
| Enterprise Value | $79,533 | $155,910 | $156,905 | $141,331 |
| Revenue | $7,509 | $6,850 | $4,365 | $3,085 |
| % Growth | 9.6% | 56.9% | 41.5% | – |
| Gross Profit | -$2,937 | -$367 | $4,148 | $2,897 |
| % Margin | -39.1% | -5.4% | 95% | 93.9% |
| EBITDA | -$20,335 | -$21,354 | -$16,988 | -$10,796 |
| % Margin | -270.8% | -311.7% | -389.2% | -350% |
| Net Income | -$21,428 | -$17,662 | -$13,077 | -$10,986 |
| % Margin | -285.4% | -257.8% | -299.6% | -356.1% |
| EPS Diluted | -0.09 | -0.1 | -0.074 | -0.063 |
| % Growth | 9.3% | -34% | -19% | – |
| Operating Cash Flow | -$20,442 | -$13,009 | -$12,687 | -$9,010 |
| Capital Expenditures | -$26 | -$142 | -$39 | -$40 |
| Free Cash Flow | -$20,468 | -$13,151 | -$12,726 | -$9,051 |